Skip to main content
UCB's Global Corporate Website
instagram
facebook
twitter
youtube
linkedin
rss
Listen
11 Sep 2020
Disposals of own shares
Read More
9 Sep 2020
Final Phase II Results for UCB’s Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) Published in Blood Advances
Read More
4 Sep 2020
Disposals of own shares
Read More
31 Aug 2020
Phase 3 data on VIMPAT[®] (lacosamide) in primary generalized tonic-clonic seizures published in Journal of Neurology, Neurosurgery & Psychiatry
Read More
28 Aug 2020
Disposals of own shares
Read More
21 Aug 2020
Disposals of own shares
Read More
10 Aug 2020
Acquisitions and disposals of own shares
Read More
5 Aug 2020
CIMZIA[®] is the First and Only Biologic Approved in Europe with the Option for a Reduced Maintenance Dose for Patients Across the Full Axial Spondyloarthritis Spectrum
Read More
30 Jul 2020
Acquisitions and disposals of own shares
Read More
30 Jul 2020
Transparency notification FMR LLC.
Read More
Pagination
First page
Previous page
‹ Previous
…
Page
10
Page
11
Page
12
Page
13
Current page
14
Page
15
Page
16
Page
17
Page
18
…
Next page
Next ›
Last page
Subscribe to
Choose a Country
Global Site – English
Australia – English
België – Engels
Belgique – Anglais
Brasil – Português
България – Български
Canada – English
Canada – Français
中国 – 中文
Česká Republika – Angličtina
Danmark – Engelsk
Deutschland – Deutsch
France – Français
España – Español
Ελλάδα – Ελληνικά
India – English
Ireland – English
Italia – Inglese
日本 – 日本語
한국 – 한국어
Luxembourg – Anglais
Luxemburg – Engels
Magyarország – Angol
México & Latinoamérica – Español
Nederland – Engels
New Zealand – English
Norge – Engelsk
Österreich – Deutsch
Polska – Polski
Portugal – español y portugués
România – Engleză
Россия – Русский
Slovensko – Anglický
Suomi – Englanti
Sverige – Engelska
Schweiz – Deutsch
Türkiye – Türkçe
Україна – Англійська
United Kingdom – English
U.S.A. – English
×
instagram
facebook
twitter
youtube
linkedin
rss